Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25884119 | 0.86 | MEN1 (0.42) | SMN1; SMN2HPGDL3MBTL1ALDH1A1 | |
| SCHEMBL24508124 | 0.85 | MEN1 (0.41) | SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL26364046 | 0.85 | MEN1 (0.41) | SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL20078293 | 0.79 | ALDH1A1 (0.38) | SMN1; SMN2GAAHPGDNPSR1L3MBTL1 | |
| SCHEMBL26502774 | 0.79 | MEN1 (0.38) | SMN1; SMN2GAAHPGDNPSR1L3MBTL1 | |
| SCHEMBL21097733 | 0.79 | MEN1 (0.40) | SMN1; SMN2GAAHPGDNPSR1L3MBTL1 | |
| SCHEMBL26261230 | 0.78 | SMN1; SMN2 (0.35) | SMN1; SMN2GAAHPGDNPSR1L3MBTL1 | |
| SCHEMBL20644803 | 0.77 | FAAH (0.43) | SMN1; SMN2GAAHPGDNPSR1ALDH1A1 | |
| SCHEMBL24193648 | 0.77 | MEN1 (0.43) | SMN1; SMN2GAAHPGDL3MBTL1ALDH1A1 | |
| SCHEMBL20644804 | 0.76 | FAAH (0.46) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315904-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315904-A1 | BCL-2 INHIBITORS | BCL2L10, BCL2, BCL2L11 | SMN1; SMN2 1293/4885GAA 2025/4885HPGD 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.